Table 2.
Median TTP, PFS, TTNT, and OS in months (95% confidence interval) in all patients and by response
| All patients (n = 155) | Responders (n = 45)a | CR/CRu (n = 11)a | PR (n = 34)a | SD (n = 52)a | PD (n = 34)a | |
| TTP | 6.7 (4.0, 7.3) | 12.4 (7.4, 16.3) | NE (14.6, NE) | 9.1 (7.4, 12.5) | 6.9 (4.2, 7.2) | 1.2 (1.2, 1.3) |
| PFS | 6.5 (4.0, 7.2) | 12.4 (7.4, 17.3) | 20.3 (14.6, NE) | 9.7 (7.2, 15.2) | 7.2 (6.4, 11.6) | 1.2 (1.2, 1.3) |
| TTNT | 7.4 (5.6, 9.3) | 14.3 (11.1, 22.6) | 23.9 (17.6, 33.9) | 13.3 (9.0, 20.5) | 7.0 (4.4, 8.7) | 2.3 (1.9, 2.9) |
| OS | 23.5 (20.3, 27.9) | 35.4 (24.9, 37.5) | 36.0 (NE, NE) | 35.1 (23.4, 37.5) | 27.8 (21.3, NE) | 13.7 (6.7, 22.3) |
a
Of the 141 response-evaluable patients, 10 had no postbaseline assessment.
TTP, time to progression; PFS, progression-free survival; TTNT, time to next therapy; OS, overall survival; CR, complete response; CRu, unconfirmed complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not estimable.